New Insights into Ivermectin and Convalescent Plasma for Outpatients with COVID-19

Two randomized trials shed further light on these interventions.

Ivermectin and convalescent plasma were proposed as treatments for COVID-19 early in the pandemic, but both have been mired in controversy and conflicting results. Now, two randomized trials provide insights into these outpatient treatments.

In the TOGETHER trial, 1358 outpatients in Brazil with COVID-19 symptoms for ≤7 days and at least 1 risk factor for severe disease were randomized between March and August 2021 to receive ivermectin (400 µg/kg/day for 3 days) or placebo. The primary endpoint (hospitalization or emergency department observation for >6 hours due to COVID-19) occurred in 14.7% and 16.3% of the ivermectin and placebo groups, respectively; this difference was not statistically significant. There were also no significant betwe…

Reviewing Author

Rajesh T. Gandhi, MD

Disclosures

Grant/Research SupportNIH

Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)

Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)

Rajesh T. Gandhi, MD

Disclosures

Grant/Research SupportNIH

Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)

Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)

New Insights into Ivermectin and Convalescent Plasma for Outpatients with COVID-19

Topics

Reviewing Author